FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898867204> ?p ?o ?g. }

• W2898867204 endingPage "535" @default.
• W2898867204 startingPage "527" @default.
• W2898867204 abstract "Although discordance in HER2 positivity between primary and metastatic lesions is well established, changes in HER2 positivity after anti-HER2 therapy have not been well evaluated in gastric cancer. We aimed to evaluate whether HER2 expression in gastric cancer is affected by trastuzumab therapy. We enrolled 48 HER2-positive advanced gastric cancer patients treated with trastuzumab-containing first-line chemotherapy and had paired biopsies at baseline and after progression. At baseline, HER2 was positive, with immunohistochemistry (IHC) 2+ and in situ hybridization (ISH)+ in five patients, and with IHC 3+ in 43 patients. Fourteen patients (29.1%) exhibited loss of HER2 positivity on post-progression biopsy: 10 with IHC 0 or 1+, and four with IHC 2+/ISH−. HER2 remained positive on second biopsy in 34 patients: four with IHC 2+/ISH+, and 30 with IHC 3+. Median H-scores decreased from 225 to 175 (p = 0.047). HER2 genetic heterogeneity was defined in one of 34 ISH-assessable patients (2.9%) at baseline and seven of 32 (21.9%) at second biopsy. Among 13 patients who received second-line trastuzumab emtansine, three showed HER2-negative conversion; they had no objective response and short progression-free survival (1.2, 1.3, and 3.4 months). Patients with stable HER2 status had a 44% response rate and median progression-free survival of 2.7 (0.4–36.8) months. A substantial portion of HER2-positive patients showed HER2-negative conversion with increased HER2 genetic heterogeneity after failure of trastuzumab-containing chemotherapy. Loss of HER2 positivity could be predictive of second-line anti-HER2 treatment, suggesting a need to reexamine HER2 status before initiating second-line anti-HER2 therapy." @default.
• W2898867204 created "2018-11-09" @default.
• W2898867204 creator A5000505018 @default.
• W2898867204 creator A5004402561 @default.
• W2898867204 creator A5005860749 @default.
• W2898867204 creator A5017172069 @default.
• W2898867204 creator A5027135040 @default.
• W2898867204 creator A5043663766 @default.
• W2898867204 creator A5060160051 @default.
• W2898867204 creator A5062088034 @default.
• W2898867204 creator A5062301570 @default.
• W2898867204 creator A5091587460 @default.
• W2898867204 date "2018-11-01" @default.
• W2898867204 modified "2023-10-13" @default.
• W2898867204 title "Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)" @default.
• W2898867204 cites W1003261060 @default.
• W2898867204 cites W1843791750 @default.
• W2898867204 cites W1969015681 @default.
• W2898867204 cites W1987009448 @default.
• W2898867204 cites W2008322008 @default.
• W2898867204 cites W2017176432 @default.
• W2898867204 cites W2019607817 @default.
• W2898867204 cites W2024326621 @default.
• W2898867204 cites W2074760070 @default.
• W2898867204 cites W2075657881 @default.
• W2898867204 cites W2076925883 @default.
• W2898867204 cites W2100439220 @default.
• W2898867204 cites W2111451083 @default.
• W2898867204 cites W2122866527 @default.
• W2898867204 cites W2125201819 @default.
• W2898867204 cites W2127773543 @default.
• W2898867204 cites W2128328462 @default.
• W2898867204 cites W2138604360 @default.
• W2898867204 cites W2140927379 @default.
• W2898867204 cites W2151809511 @default.
• W2898867204 cites W2160896330 @default.
• W2898867204 cites W2169344919 @default.
• W2898867204 cites W2203369285 @default.
• W2898867204 cites W2277062443 @default.
• W2898867204 cites W2281897907 @default.
• W2898867204 cites W2324445651 @default.
• W2898867204 cites W2507354993 @default.
• W2898867204 cites W2513840682 @default.
• W2898867204 cites W2587915970 @default.
• W2898867204 cites W2598685895 @default.
• W2898867204 cites W2917837889 @default.
• W2898867204 doi "https://doi.org/10.1007/s10120-018-0891-1" @default.
• W2898867204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30386954" @default.
• W2898867204 hasPublicationYear "2018" @default.
• W2898867204 type Work @default.
• W2898867204 sameAs 2898867204 @default.
• W2898867204 citedByCount "75" @default.
• W2898867204 countsByYear W28988672042018 @default.
• W2898867204 countsByYear W28988672042019 @default.
• W2898867204 countsByYear W28988672042020 @default.
• W2898867204 countsByYear W28988672042021 @default.
• W2898867204 countsByYear W28988672042022 @default.
• W2898867204 countsByYear W28988672042023 @default.
• W2898867204 crossrefType "journal-article" @default.
• W2898867204 hasAuthorship W2898867204A5000505018 @default.
• W2898867204 hasAuthorship W2898867204A5004402561 @default.
• W2898867204 hasAuthorship W2898867204A5005860749 @default.
• W2898867204 hasAuthorship W2898867204A5017172069 @default.
• W2898867204 hasAuthorship W2898867204A5027135040 @default.
• W2898867204 hasAuthorship W2898867204A5043663766 @default.
• W2898867204 hasAuthorship W2898867204A5060160051 @default.
• W2898867204 hasAuthorship W2898867204A5062088034 @default.
• W2898867204 hasAuthorship W2898867204A5062301570 @default.
• W2898867204 hasAuthorship W2898867204A5091587460 @default.
• W2898867204 hasBestOaLocation W28988672041 @default.
• W2898867204 hasConcept C121608353 @default.
• W2898867204 hasConcept C126322002 @default.
• W2898867204 hasConcept C142724271 @default.
• W2898867204 hasConcept C143998085 @default.
• W2898867204 hasConcept C204232928 @default.
• W2898867204 hasConcept C2775934546 @default.
• W2898867204 hasConcept C2776694085 @default.
• W2898867204 hasConcept C2779786085 @default.
• W2898867204 hasConcept C2780140570 @default.
• W2898867204 hasConcept C530470458 @default.
• W2898867204 hasConcept C71924100 @default.
• W2898867204 hasConcept C90924648 @default.
• W2898867204 hasConceptScore W2898867204C121608353 @default.
• W2898867204 hasConceptScore W2898867204C126322002 @default.
• W2898867204 hasConceptScore W2898867204C142724271 @default.
• W2898867204 hasConceptScore W2898867204C143998085 @default.
• W2898867204 hasConceptScore W2898867204C204232928 @default.
• W2898867204 hasConceptScore W2898867204C2775934546 @default.
• W2898867204 hasConceptScore W2898867204C2776694085 @default.
• W2898867204 hasConceptScore W2898867204C2779786085 @default.
• W2898867204 hasConceptScore W2898867204C2780140570 @default.
• W2898867204 hasConceptScore W2898867204C530470458 @default.
• W2898867204 hasConceptScore W2898867204C71924100 @default.
• W2898867204 hasConceptScore W2898867204C90924648 @default.
• W2898867204 hasIssue "3" @default.
• W2898867204 hasLocation W28988672041 @default.
• W2898867204 hasLocation W28988672042 @default.
• W2898867204 hasOpenAccess W2898867204 @default.

• next